Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF), a leader in mental health care, will participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022, in San Francisco. Founder and CEO Payton Nyquvest will feature in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on October 7 at 9:00 a.m. PT. Numinus will also partake in a virtual fireside chat during the Cantor Symposium on Mental Health Clinics on October 11, 2022, at 11:00 a.m. ET. The company focuses on innovative, evidence-based psychedelic-assisted therapies aimed at mental health improvement.
- None.
- None.
VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.
Payton Nyquvest, Founder and CEO of Numinus, will participate in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on Friday, October 7th at 9:00 a.m. PT.
In addition, Numinus will participate in the Cantor Symposium on Mental Health Clinics on Tuesday, October 11, 2022. Mr. Nyquvest will participate in a virtual fireside chat with Pablo Zuanic, Cantor Research Analyst, at 11:00 a.m. ET / 8:00 a.m. PT. To attend, please register here:
https://us06web.zoom.us/webinar/register/WN_j0ChDwu_Tn6EFJfMUYjfqA
For more information about the conference, or to schedule a one-on-one meeting with Numinus' management, please contact your appropriate Cantor representative directly, or send an email to KCSA Strategic Communications NuminusIR@kcsa.com.
About Numinus
Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
Forward-looking statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/numinus-to-participate-in-the-cantor-neurology--psychiatry-conference-on-october-6-7-2022-301637068.html
SOURCE Numinus Wellness Inc.
FAQ
What dates will Numinus participate in the Cantor Neurology & Psychiatry Conference?
Who from Numinus is speaking at the conference?
What is the topic of Payton Nyquvest's panel at the conference?
When is the virtual fireside chat with Numinus?
What are the stock symbols for Numinus?
